Catalyst Pharmaceuticals Inc.
Rating
Updated: May 25, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, a...
Latest News
2 months ago · reuters.com
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of CatalystAngelini Pharma said on Thursday it had completed the acquisition of U.S. rare-disease drug maker Catalyst Pharmaceuticals in a $4.1 billion deal involving Italian state lender CDP.
2 months ago · globenewswire.com
Angelini Pharma Completes Acquisition of Catalyst PharmaceuticalsThe Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare Diseases Completion of the transaction gives Angelini Pharma ownership of Catalyst's product portfolio The transaction is being carried out with the participation of funds managed by Blackstone CDP Equity approves €1 billion investment in Angelini Pharma Italy remains a strategic production and scientific hub ROME and CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Angelini Pharma S.p.A.
3 months ago · marketbeat.com
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma MergerCatalyst Pharmaceuticals NASDAQ: CPRX stockholders approved the company's proposed merger with Angelini Pharma S.p.A. at a special meeting held virtually on July 8, according to remarks from company officials during the meeting.
3 months ago · zacks.com
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I DataCatalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.
3 months ago · gurufocus.com
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc. - CPRXFormer Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propo
4 months ago · zacks.com
Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue?Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
4 months ago · zacks.com
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
4 months ago · zacks.com
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-TermWhether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
4 months ago · zacks.com
CPRX or UTHR: Which Is the Better Value Stock Right Now?Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks presents investors with the better value opportunity right now?
4 months ago · zacks.com
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/YCPRX beats Q1 estimates driven by rising Firdapse and Agamree sales amid Angelini Pharma's pending $4.1B acquisition deal.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove CPRX